Zavante Therapeutics names Scientific Advisory Board

Zavante Therapeutics, a privately owned biopharmaceutical company that conducts late-stage clinical trials, has appointed eight infectious disease specialists to serve on its newly formed Scientific Advisory Board.
The infectious disease specialists will serve as strategic and scientific resources for Zavante.
"We are pleased to bring together this strong team of infectious disease specialists to support the development efforts of ZTI-01, our lead product candidate," Zavante CEO Ted Schroeder said. "We believe ZTI-01, a first-in-class injectable antibiotic, will provide additional treatment options in the hospital setting where current therapeutic choices are severely limited."
ZTI-01, an investigational antibiotic, is in development to treat patients who have been hospitalized due to complicated urinary tract infections. This also includes acute pyelonephritis.
Zavante’s inaugural members of its Scientific Advisory Board include Paul Ambrose, John Bradley, George Drusano, Ronald Jones, Keith Rodvold, Albert Sheldon, Andrew Shorr and Robert Flamm. A full biography on each new member of the Scientific Advisory Board can be found at www.zavante.com/sab.